4EGI-1 - CAS 315706-13-9
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
4EGI-1
Catalog Number:
B0084-463344
Synonyms:
4EGI-1
CAS Number:
315706-13-9
Description:
4EGI-1 is a competitive eIF4E/eIF4G interaction inhibitor by binding to eIF4E with KD of 25 μM.
Molecular Weight:
451.28
Molecular Formula:
C18H12Cl2N4O4S
COA:
Inquire
MSDS:
Inquire
Targets:
Others
Catalog Number Size Price Stock Quantity
B0084-463344 25 mg $188 In stock
Bulk Inquiry
Chemical Structure
CAS 315706-13-9 4EGI-1

Related Products


CAS 3606-45-9 Dihydrosanguinarine

Dihydrosanguinarine
(CAS: 3606-45-9)

Dihydrosanguinarine (DHSG) is a metabolite of Sanguinarine with antifungal activity.

CAS 102767-28-2 Levetiracetam

Levetiracetam
(CAS: 102767-28-2)

Levetiracetam is an anticonvulsant medication used to treat epilepsy.

LY 193239
(CAS: 124986-46-5)

This bio-active molecular is a cell wall inhibitor as a antibacterial agent. LY 193239 has a lactam pyrazolidinone structure. Clinical trials for Bacterial infe...

CAS 12192-57-3 Aurothioglucose

Aurothioglucose
(CAS: 12192-57-3)

Aurothioglucose is used in the treatment of rheumatoid arthritis and psoriasis.

CAS 13647-35-3 Trilostane

Trilostane
(CAS: 13647-35-3)

Trilostane is an inhibitor of 3β-hydroxysteroid dehydrogenase used in the treatment of Cushing’s syndrome.

CAS 36062-04-1 Tetrahydrocurcumin

Tetrahydrocurcumin
(CAS: 36062-04-1)

Tetrahydrocurcumin is being studied for the treatment of cancer and dementia. It has antioxidant and anti-inflammatory properties. Tetrahydrocurcumin has been s...

CAS 867257-26-9 Tecarfarin

Tecarfarin
(CAS: 867257-26-9)

Tecarfarin is a vitamin K epoxide reductase inhibitor. It can attenuate venous and arterial thrombus formation in animal models by reducing the levels of the vi...

CAS 43218-56-0 Midodrine (hydrochloride)

Midodrine (hydrochloride)
(CAS: 43218-56-0)

Midodrine is an α1-receptor agonist and exerts its actions via activation of the alpha-adrenergic receptors of the arteriolar and venous vasculature.

CAS 168021-79-2 Disufenton Sodium

Disufenton Sodium
(CAS: 168021-79-2)

The sodium salt form of Disufenton, a benzenesulfonate compound, has been found to be a free radical scavenger that was once studied in acute ischaemic stroke t...

AT-1459
(CAS: 294658-50-7)

AT-1459 is a novel, direct thrombin inhibitor with antithrombotic efficacy (Ki = 4.9 nM).

CAS 4618-18-2 Lactulose

Lactulose
(CAS: 4618-18-2)

Lactulose, a disaccharide composed of galactose and fructose, is a stimulator of health-promoting bacterium growth in the gastrointestinal tract, used to treat ...

CAS 3685-84-5 Meclofenoxate hydrochloride

Meclofenoxate hydrochloride
(CAS: 3685-84-5)

Meclofenoxate (Lucidril), also known as centrophenoxine, is a drug used to treat the symptoms of senile dementia and Alzheimer's disease. It is an ester of dime...

CAS 472-26-4 Telocinobufagin

Telocinobufagin
(CAS: 472-26-4)

Telocinobufagin is one of anti-hepatoma constituent in Venenum Bufonis.

CAS 1146963-51-0 J 147

J 147
(CAS: 1146963-51-0)

J 147, under the IUPAC name N-(2,4-dimethylphenyl)-2,2,2-trifluoro-N-[(E)-(3-methoxyphenyl)methylideneamino]acetamide, a phenyl hydrazide compound that has been...

Vatiquinone
(CAS: 1213269-98-7)

This active molecular has a para-benzoquinone structure and was developed for inherited mitochondrial diseases base on vitamin E. The mechanism of action of Vat...

MI-538
(CAS: 1857417-10-7)

MI-538, a 4-methylpyrazole compound, is a double substituted analogue with methylpyrazole at R1 and hydroxyl at R4. MI-538, a potent and selective MLL (Mixed Li...

CAS 53-19-0 Mitotane

Mitotane
(CAS: 53-19-0)

Mitotane, is an antineoplastic medication used in the treatment of adrenocortical carcinoma.

PD 142505-0028
(CAS: 161774-09-0)

PD 142505-0028, also know as CI-1017, has been found to be a muscarinic agonist that could exhibit effect against cognition disorder so that was once studied in...

CAS 18010-40-7 Bupivacaine HCl

Bupivacaine HCl
(CAS: 18010-40-7)

Bupivacaine HCl binds to the intracellular portion of voltage-gated sodium channels and blocks sodium influx into nerve cells, used for treating cardiac arrhyth...

Reference Reading


1.Abberant protein synthesis in G2019S LRRK2 Drosophila Parkinson disease-related phenotypes.
Martin I1, Abalde-Atristain L, Kim JW, Dawson TM, Dawson VL. Fly (Austin). 2014;8(3):165-9. doi: 10.4161/19336934.2014.983382.
LRRK2 mutations are a frequent cause of familial Parkinson disease (PD) and are also found in a number of sporadic PD cases. PD-linked G2019S and I2020T mutations in the kinase domain of LRRK2 result in elevated kinase activity, which is required for the toxicity of these pathogenic variants in cell and animal models of PD. We recently reported that LRRK2 interacts with and phosphorylates a number of mammalian ribosomal proteins, several of which exhibit increased phosphorylation via both G2019S and I2020T LRRK2. Blocking the phosphorylation of ribosomal protein s15 through expression of phospho-deficient T136A s15 prevents age-associated locomotor deficits and dopamine neuron loss caused by G2019S LRRK2 expression in Drosophila indicating that s15 is a pathogenic LRRK2 substrate. We previously described that G2019S LRRK2 causes an induction of bulk mRNA translation that is blocked by T136A s15 or the protein synthesis inhibitor anisomycin.
2.The synergistic inhibition of breast cancer proliferation by combined treatment with 4EGI-1 and MK2206.
Wang H1, Huang F, Wang J, Wang P, Lv W, Hong L, Li S, Zhou J. Cell Cycle. 2015;14(2):232-42. doi: 10.4161/15384101.2014.977096.
Cap-dependent translation is a potential cancer-related target (oncotarget) due to its critical role in cancer initiation and progression. 4EGI-1, an inhibitor of eIF4E/eIF4G interaction, was discovered by screening chemical libraries of small molecules. 4EGI-1 inhibits cap-dependent translation initiation by impairing the assembly of the eIF4E/eIF4G complex, and therefore is a potential anti-cancer agent. Here, we report that 4EGI-1 also inhibits mTORC1 signaling independent of its inhibitory role on cap-dependent translation initiation. The inhibition of mTORC1 signaling by 4EGI-1 activates Akt due to both abrogation of the negative feedback loops from mTORC1 to PI3K and activation of mTORC2. We further validated that mTORC2 activity is required for 4EGI-1-mediated Akt activation. The activated Akt counteracted the anticancer effects of 4EGI-1. In support of this model, inhibition of Akt potentiates the antitumor activity of 4EGI-1 both in vitro and in a xenograft mouse model in vivo.
3.4EGI-1 induces apoptosis and enhances radiotherapy sensitivity in nasopharyngeal carcinoma cells via DR5 induction on 4E-BP1 dephosphorylation.
Wang W1, Li J1, Wen Q1, Luo J1, Chu S1, Chen L1, Qing Z2, Xie G2, Xu L1, Alnemah MM1, Li M1, Fan S1, Zhang H1. Oncotarget. 2016 Mar 1. doi: 10.18632/oncotarget.7824. [Epub ahead of print]
The eIF4F complex regulated by a various group of eIF4E-binding proteins (4E-BPs) can initial the protein synthesis. Small molecule compound 4EGI-1, an inhibitor of the cap-dependent translation initiation through disturbing the interaction between eIF4E and eIF4G which are main elements of the eIF4E complex, has been reported to suppress cell proliferation by inducing apoptosis in many types of cancer. And death receptor 5 (DR5) is a major component in the extrinsic apoptotic pathway. However, the correlation among 4EGI-1, DR5 and 4E-BPs have not been discovered in NPC now. Therefore, we intend to find out the effect of 4EGI-1 on the apoptosis process of NPC and the relationship among 4EGI-1, DR5 and 4E-BPs. Our results revealed a significant down regulation of DR5 expression in NPC tissues, which inversely correlated with lymph node metastasis status and clinical stages. Depressed DR5 expression was an independent biomarker for poor prognosis in NPC, and elevated DR5 expression showed longer overall survival time in 174 NPC patients.
4.Cytotoxicity Induced by a Redox-silent Analog of Tocotrienol in Human Mesothelioma H2452 Cell Line via Suppression of Cap-dependent Protein Translation.
Sato A1, Ueno H2, Takase A2, Ando A3, Sekine Y4, Yano T5. Anticancer Res. 2016 Apr;36(4):1527-33.
De novo synthesis of proteins is regulated by cap-dependent protein translation. Aberrant activation of the translation is a hallmark of many cancer types including malignant mesothelioma (MM). We previously reported that a redox-silent analog of α-tocotrienol, 6-O-carboxypropyl-α-tocotrienol (T3E) induces potent cytotoxicity against human MM cells. However, the detailed mechanism of cytotoxicity of T3E remains unclear. In this study, we investigated if T3E induced potent cytotoxicity aganist MM cells. T3E reduced the formation of the cap-dependent translation complex and induced inactivation of oncogene from rat sarcoma virus (RAS). These events were associated with T3E cytotoxicity in MM cells. Furthermore, atorvastatin, an inhibitor of RAS function, had similar effects on MM cells. Moreover, 4EGI-1, a specific inhibitor of the cap-dependent translation complex, induced severe cytotoxicity in MM cells. Overall, T3E had a cytotoxic effect on MM cells via disruption of the activated cap-dependent translation complex through inactivation of RAS.